ADDUCE
Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects
| Coordinatore | UNIVERSITY OF DUNDEE
Organization address
address: Nethergate contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 3˙929˙356 € |
| EC contributo | 2˙999˙559 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-11-01 - 2016-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF DUNDEE
Organization address
address: Nethergate contact info |
UK (DUNDEE) | coordinator | 746˙518.60 |
| 2 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 349˙200.00 |
| 3 |
ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Organization address
address: Square J 5 contact info |
DE (MANNHEIM) | participant | 315˙194.40 |
| 4 |
VADASKERT ALAPITVANY A GYERMEKEK LELKI EGESZSEGEERT
Organization address
address: HUVOSVOLGYI UT 116 contact info |
HU (BUDAPEST) | participant | 309˙600.00 |
| 5 |
UNIVERSITA DEGLI STUDI DI CAGLIARI
Organization address
address: VIA UNIVERSITA 40 contact info |
IT (CAGLIARI) | participant | 301˙260.00 |
| 6 |
GUYS AND ST THOMAS' NHS FOUNDATIONTRUST
Organization address
address: Westminster Bridge Road contact info |
UK (London) | participant | 196˙800.00 |
| 7 |
"THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON"
Organization address
address: Brunswick Square 29-39 contact info |
UK (LONDON) | participant | 171˙790.00 |
| 8 |
UNIVERSITAETSKLINIKUM AACHEN
Organization address
address: Pauwelsstrasse 30 contact info |
DE (AACHEN) | participant | 129˙885.00 |
| 9 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 119˙714.00 |
| 10 |
THE UNIVERSITY OF NOTTINGHAM
Organization address
address: University Park contact info |
UK (NOTTINGHAM) | participant | 111˙201.60 |
| 11 |
UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
Organization address
address: Western Road contact info |
IE (CORK) | participant | 79˙200.00 |
| 12 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 75˙600.00 |
| 13 |
ISTITUTO SUPERIORE DI SANITA
Organization address
address: Viale Regina Elena 299 contact info |
IT (ROMA) | participant | 33˙900.00 |
| 14 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 30˙000.00 |
| 15 |
Therakind Ltd
Organization address
address: DOLLIS PARK ROAD WINSTON HOUSE 2 contact info |
UK (London) | participant | 24˙000.00 |
| 16 |
STICHTING EUNETHYDIS FOUNDATION
Organization address
address: Ign Bispincklaan 11 contact info |
NL (Bloemendaal) | participant | 5˙696.00 |
| 17 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use (CHMP) under Article 31 of Directive 2001/83/EC, as amended, for MPH because of safety concerns. The CHMP concluded that study of the long-term effects of MPH on growth, sexual development, neurological system, psychiatric states and cardiovascular system is needed. In response to the CHMP’s concerns, the ADDUCE (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects) research team has been formed by a consortium of experts in the fields of ADHD, drug safety, neuropsychopharmacology and cardiovascular research. The ADDUCE project aims to investigate the long-term adverse effects of MPH on growth, neurological system, psychiatric states and cardiovascular system in children and adults. The ADDUCE team will use multiple pharmacoepidemiological research methods to achieve its aim: (1) Retrospective analysis of existing databases. (2) 2-year prospective cohort study recruiting 800 MPH-treated children and adolescents and 800 controls. (3) Cross-sectional study (600 MPH-treated patients and 600 controls) in late adolescents and young adults. Furthermore the ADDUCE team will develop research tools for the evaluation of adverse effects of MPH on cognition and motivation. The ADDUCE consortium comprises 12 academic partners, 1 SME and 1 EU professional network. The ADDUCE team will directly interact with the European Medicines Agency to assist them in making regulatory decisions on the safety of MPH in children and adults. The ADDUCE team will adopt an open-access policy to ensure the information and results have the maximum public health impact.'